Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval ... nations for various indications encompassing asthma, prurigo nodularis, chronic rhinosinusitis ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

Dupilumab (Dupixent ... meaning it's advisable to not take it – in people with severe asthma, helminthic parasite infections, eosinophilic pneumonia or vasculitis, and people taking live ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Spring starts with the time change, and while it's nice now to have hours of additional sunlight every day, losing that hour ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Phase 2b trials in atopic dermatitis and asthma are planned to start in the ... STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Th2 biomarkers ...